about
Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trialHaemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.Persistent sympathoexcitation long after submaximal exercise in subjects with and without coronary artery diseaseRecovery of heart rate variability and ventricular repolarization indices following exercise.Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.Circadian and gender effects on repolarization in healthy adults: a study using harmonic regression analysis.Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy.Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease.Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).Prognostic value and temporal behavior of the planar QRS-T angle in patients with nonischemic cardiomyopathy.Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators.Improvements in health-related quality of life before and after isolated cardiac operations.Clinical characteristics and prevalence of early repolarization associated with ventricular arrhythmias following acute ST-elevation myocardial infarction.Unique autonomic profile of the pulmonary veins and posterior left atriumA new method to determine the electrical transfer function of the human thoraxContemporary perioperative results of isolated aortic valve replacement for aortic stenosisVentricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudyEarly repolarization associated with ventricular arrhythmias in patients with chronic coronary artery diseaseThe Trauma Center Organizational Culture Survey: development and conductionDetection of cardiovascular autonomic neuropathy using exercise testing in patients with type 2 diabetes mellitusSignificance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE)Should an improvement in left ventricular systolic function preclude ICD generator replacement?
P50
Q33153551-CBCA5656-6C8D-479D-8536-7AE507116E0DQ34152481-0836B9AB-8348-4A4A-A7E2-72D15D076E27Q34248419-876EB8E7-FBFE-4D90-8125-D6234C06CE6EQ34350739-B05AEEAA-1330-4C3E-BFE7-4D19FCBBBDBDQ35315269-D2980CC8-5C83-45DB-9FAA-CD7178A139D7Q36347425-62D80678-D9E5-4E1C-A4B1-2747F7F7C759Q44465520-8A2D5CA1-EA0D-49B3-9A0C-76B95A79D140Q44886447-A5DADEE8-9C02-462C-B6EA-E75D55816F84Q45306207-EB682EA5-0F43-4A30-850C-6E5B8E0F5483Q45368659-17337CEC-463F-4FB7-831C-C632A5AA00DAQ45770684-DA0C00AC-FD25-4C39-8234-E428ED672BD2Q46406310-E8795B70-7330-48AF-8971-0A9C9A68FBACQ46846776-FCEF2460-96AB-40EE-AFE0-63F162625DE6Q47618032-00EBC91C-AC04-4BA4-8BD4-2D815FADBFB1Q50866712-E7A77ECD-F5B1-4C40-B74E-D20CDEC4B5CAQ51179026-3DB8837A-EC8F-4F42-96A5-EBBFDEF7B10EQ51812140-9598F456-ACB2-497C-AEE9-3CF5DD85A1A2Q54507290-AC4C123C-5FA8-4323-B9E6-A8DA95F12302Q80063640-B5C831BB-8CF6-4201-8E6C-6E57B675234EQ81435408-E78DF118-6A27-4517-BDC8-017D6D825BBEQ82978173-6EAE205E-51B2-4735-9FCC-E7B9A69713D6Q84103804-24731EF6-44F7-4EDA-923A-4C095D3A5D15Q84592104-F162C07B-14F1-4256-B879-7BAB1C682CE7Q85206789-DBC9F177-F079-40C7-AFED-F9A49D90B6BEQ85236102-0095511A-CADA-4D6D-8790-333A561FCB2AQ86166029-514C0CD5-84F8-480F-ACF3-F195666C6FFCQ95385706-775D607E-0B19-407F-9C35-AD23256A8B29
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Haris Subacius
@ast
Haris Subacius
@en
Haris Subacius
@es
Haris Subacius
@nl
Haris Subacius
@sl
type
label
Haris Subacius
@ast
Haris Subacius
@en
Haris Subacius
@es
Haris Subacius
@nl
Haris Subacius
@sl
prefLabel
Haris Subacius
@ast
Haris Subacius
@en
Haris Subacius
@es
Haris Subacius
@nl
Haris Subacius
@sl
P106
P21
P31
P496
0000-0003-4061-1220
P569
2000-01-01T00:00:00Z